



July 16, 2025

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

We are pleased to enclose a Press Release as regards, launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States.

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com

Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States

Mumbai, Naples, July 16, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax® Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc.

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.

It is also indicated for the treatment of post-operative inflammation following ocular surgery.

Loteprednol Etabonate Ophthalmic Suspension (RLD Lotemax®) had estimated annual sales of USD 55 million in the U.S. (IQVIA MAT May 2025).

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

For further information or queries please contact –

Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin

rajalakshmi.azariah@lupin.com

***Safe Harbor Statement**

Lotemax® is a registered trademark of Bausch & Lomb Incorporated